These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
431 related items for PubMed ID: 12831297
1. [Observational study on the efficacy of the application of two classical regimens of triple antiretroviral therapy]. Eiros Bouza JM, Ortega Lafont M, Ortiz de Lejarazu R, Bachiller Luque P, de Luis Román DA. An Med Interna; 2003 May; 20(5):239-42. PubMed ID: 12831297 [Abstract] [Full Text] [Related]
2. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients. Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group. Antivir Ther; 1999 May; 4 Suppl 3():71-4. PubMed ID: 16021874 [Abstract] [Full Text] [Related]
3. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients. AIDS; 2000 Mar 10; 14(4):367-74. PubMed ID: 10770538 [Abstract] [Full Text] [Related]
4. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes. Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P. Antivir Ther; 2005 Mar 10; 10(8):911-6. PubMed ID: 16430196 [Abstract] [Full Text] [Related]
5. Successful simplification of HAART in patients with acute primary HIV infection. Sinicco A, Bonora S, Arnaudo I, Zeme DA, Audagnotto S, Raiteri R, Di Perri G. J Biol Regul Homeost Agents; 2002 Mar 10; 16(1):69-72. PubMed ID: 12003178 [Abstract] [Full Text] [Related]
6. [Drug combination therapy for children infected with HIV/AIDS--own experience]. Prandota-Schoepp A, Klinowska-Skupniewska J. Przegl Epidemiol; 2001 Mar 10; 55 Suppl 3():135-41. PubMed ID: 11984940 [Abstract] [Full Text] [Related]
7. Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine. Coplan PM, Cook JR, Carides GW, Heyse JF, Wu AW, Hammer SM, Nguyen BY, Meibohm AR, DiNubile MJ, AIDS Clinical Trials Group 320 Study Team. Clin Infect Dis; 2004 Aug 01; 39(3):426-33. PubMed ID: 15307012 [Abstract] [Full Text] [Related]
8. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy. de Mendoza C, Soriano V, Pérez-Olmeda M, Rodés B, Casas E, González-Lahoz J. J Hum Virol; 1999 Aug 01; 2(6):344-9. PubMed ID: 10774551 [Abstract] [Full Text] [Related]
9. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, Ruef C, Zimmerli S. AIDS Res Hum Retroviruses; 1999 Dec 10; 15(18):1631-8. PubMed ID: 10606086 [Abstract] [Full Text] [Related]
10. Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine. Bocket L, Yazdanpanah Y, Ajana F, Gerard Y, Viget N, Goffard A, Alcaraz I, Wattré P, Mouton Y. J Antimicrob Chemother; 2004 Jan 10; 53(1):89-94. PubMed ID: 14645320 [Abstract] [Full Text] [Related]
11. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see. Prescrire Int; 2004 Oct 10; 13(73):180-2. PubMed ID: 15499699 [Abstract] [Full Text] [Related]
12. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Jaspan HB, Berrisford AE, Boulle AM. Pediatr Infect Dis J; 2008 Nov 10; 27(11):993-8. PubMed ID: 18818556 [Abstract] [Full Text] [Related]
13. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients. de Mendoza C, Soriano V, Pérez-Olmeda M, Rodríguez-Rosado R, González-Lahoz J. J Hum Virol; 2000 Nov 10; 3(6):335-40. PubMed ID: 11100914 [Abstract] [Full Text] [Related]
14. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks. Murphy RL. Antivir Ther; 1999 Nov 10; 4 Suppl 3():85-7. PubMed ID: 16021877 [Abstract] [Full Text] [Related]
15. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus. Molina JM, Chêne G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM. J Infect Dis; 1999 Aug 10; 180(2):351-8. PubMed ID: 10395849 [Abstract] [Full Text] [Related]
16. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial. Flandre P, Peytavin G, Meiffredy V, Saidi Y, Descamps D, Delagnes M, Brun-Vézinet F, Raffi F, Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. Antivir Ther; 2002 Jun 10; 7(2):113-21. PubMed ID: 12212923 [Abstract] [Full Text] [Related]
20. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine. Sproat M, Pozniak AL, Peeters M, Winters B, Hoetelmans R, Graham NM, Gazzard BG. Antivir Ther; 2005 Jun 10; 10(2):357-61. PubMed ID: 15865231 [Abstract] [Full Text] [Related] Page: [Next] [New Search]